AMSTERDAM, Jan 30 (Reuters) - Shares in Dutch biotechnology firm OctoPlus rose as much as 9 percent on Tuesday after the company said it would start a Phase IIa clinical study with its hepatitis C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback